12:00 AM
 | 
Jan 08, 2001
 |  BioCentury  |  Tools & Techniques

CVT's power play

Investors punished CV Therapeutics Inc. on Friday's announcement that the company will enroll additional patients in its second Phase III trial of ranolazine, treating the news as if it were just another case of a biotech company trying to manipulate a failing study. But in its defense, the company says it had prospectively built in the possibility of adding more patients as a precautionary move to maintain the power of the trial.

The CARISA trial (Combination Assessment of Ranolazine in Stable Angina) is testing ranolazine, a pFOX (partial fatty acid oxidation) inhibitor, in combination with other anti-angina drugs...

Read the full 474 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >